VHL Gene Mutations in Renal Cell Carcinoma: Role as a Biomarker of Disease Outcome and Drug Efficacy

被引：120
作者：
Cowey, C. Lance [1 ]
Rathmell, W. Kimryn [1 ]
机构：
[1] Lineberger Canc Ctr, Chapel Hill, NC 27599 USA
来源：
CURRENT ONCOLOGY REPORTS | 2009年 / 11卷 / 02期
关键词：
TUMOR-SUPPRESSOR GENE; HIPPEL-LINDAU GENE; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE GENES; SOMATIC MUTATIONS; INTERFERON-ALPHA; CANCER; IDENTIFICATION; PROGNOSIS; THERAPY;
D O I：
10.1007/s11912-009-0015-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.
引用
收藏
页码：94 / 101
页数：8
相关论文
共 48 条
  • [1] Brauch H, 2000, CANCER RES, V60, P1942
  • [2] Bukowski R M, 2001, Semin Urol Oncol, V19, P148
  • [3] VEGF as a key mediator of angiogenesis in cancer
    Carmeliet, P
    [J]. ONCOLOGY, 2005, 69 : 4 - 10
  • [4] CHEN F, 1995, CANCER RES, V55, P4804
  • [5] The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer
    Cho, Daniel
    Signoretti, Sabina
    Regan, Meredith
    Mier, James W.
    Atkins, Michael B.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (02) : 758S - 763S
  • [6] von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
    Choueiri, Toni K.
    Vaziri, Susan A. J.
    Jaeger, Erich
    Elson, Paul
    Wood, Laura
    Bhalla, Ish Prasad
    Small, Eric J.
    Weinberg, Vivian
    Sein, Nancy
    Simko, Jeff
    Golshayan, Ali-Reza
    Sercia, Linda
    Zhou, Ming
    Waldman, Frederic M.
    Rini, Brian I.
    Bukowski, Ronald M.
    Ganapathi, Ram
    [J]. JOURNAL OF UROLOGY, 2008, 180 (03) : 860 - 865
  • [7] Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO
  • [8] 2-#
  • [9] Using molecular biology to develop drugs for renal cell carcinoma
    Cowey, C. Lance
    Rathmell, W. Kimryn
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (03) : 311 - 327
  • [10] Promoter hypermethylation profile of kidney cancer
    Dulaimi, E
    Ibanez de Caceres, I
    Uzzo, RG
    Al-Saleem, T
    Greenberg, RE
    Polascik, TJ
    Babb, JS
    Grizzle, WE
    Cairns, P
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (12) : 3972 - 3979
12345